… (ie PD-1 and CTLA-4), there are newly recognized alternative checkpoints that provide
additional opportunities for study and treatment. Characterizations of GBM and TILs within the …

… Despite preliminary investigations gave promising results, the major challenges of the … (49,
50) providing a window of opportunity for anti-PD-L1/PD-1 inhibitor treatment by diminishing …

… -presentation, inhibits detection, and inhibits activation of the … system is creating many new
therapeutic opportunities. … meaningful outcomes continues to be challenging. Combinations of …

… Traditionally, radical resection of the primary tumor has a higher opportunity to thoroughly
remove … Frequently used immunotherapies for OS include immune checkpoint inhibitors (ICIs), …

… We also suggest ways that antiangiogenic agents can be combined with immune-checkpoint
inhibitors to potentially improve patient outcomes, and highlight avenues of future research. …

… classes of immune checkpoint inhibitors, chimeric antigen … to identify current opportunities
and challenges with the goal of … -priority areas of current opportunity for the field: mechanisms …

… that responses with PD-1 checkpoint blockade alone will unlikely … challenges posed by
the T-cell lymphoproliferative disorders and discuss potential strategies to optimize checkpoint …

… Over the last few years, the development of immunotherapy has revolutionized lung
cancer treatment (5), with four different immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 …

… time creates opportunities for targeting by checkpoint inhibitors. … checkpoint inhibitors is a
largely unexplored area and may yield exciting novel insights, although it will be challenging …

… of the tsunami of immune checkpoint inhibitors, 2016 was … on debatable issues related to
checkpoint inhibitors, since the first … Finally, the impact of checkpoint inhibitors development on …